Vitamin D receptor rs2228570 polymorphism is associated with LH levels in men exposed to anabolic androgenic steroids

Linda Björkhem-Bergman1*, Mikael Lehtihet2, Anders Rane3 and Lena Ekström3

Abstract

Objective: The primary aim of this study was to investigate the association between the vitamin D receptor polymorphisms rs2228570 (Fok1) and rs731236 (TaqI) and LH and FSH levels in relation to anabolic androgenic steroid (AAS) use.

Results: Two cohorts were analyzed. Cohort 1 comprised healthy volunteers given single supra-physiological doses of 500 mg testosterone (n = 25). Cohort 2 comprised 45 self-reporting AAS users. Healthy volunteers homozygous for the C-allele of the Fok1 polymorphism exhibited 30% higher LH levels than T-carriers at baseline (p = 0.04) and twice the levels 14 days after testosterone administration (p = 0.01). AAS users homozygous for the C-allele had four times higher LH levels than TT-individuals (p < 0.05). FSH levels were not associated with Fok1 polymorphism, nor were LH and FSH levels associated with the TaqI polymorphism. In conclusion, there is an association between LH levels and the Fok1 VDR polymorphism and this difference is even more pronounced in AAS users and subjects with suppressed LH levels.

Keywords: Vitamin D receptor, rs2228570, rs731236, Anabolic androgenic steroid, Hypogonadism, LH, FSH

Introduction

It is generally known that the use of anabolic androgenic steroids (AAS) suppresses the secretion of the pituitary luteinizing hormone (LH) and follicle stimulating hormone (FSH). This effect results from a negative feedback of androgens on the hypothalamic-pituitary–gonadal (HPG) axis. We recently showed that already a single dose of intra-muscular administration of testosterone or nandrolone suppresses the secretion of LH and FSH, but with large inter-individual variations [1, 2]. After discontinuation of AAS use, LH and FSH may be suppressed for a long period of time, resulting in anabolic steroid induced hypogonadism (ASIH) [3]. The time of AAS induced hypogonadotropic hypogonadism is highly variable and is dependent on the duration, dose and type of steroids used, co-use of other drugs and age, but may also be influenced by genetic factors [4–6].

Several studies have shown that vitamin D deficiency is associated with low testosterone levels in men [5, 7] which may be accompanied by low levels of gonadotropins [8]. Vitamin D exhibits its effect by binding to the vitamin D receptor (VDR). A previous study reported that a single nucleotide polymorphism (SNP) rs731236 (also known as TaqI) in VDR was associated with serum LH concentration but not with FSH concentrations in women with polycystic ovarian syndrome (PCOS) [9]. This polymorphism is a silent T > C SNP located in exon 9 and affects the function of VDR, probably due to an altered expression profile [10].

The VDR genotype rs2228570 (also known as Fok1) is a C > T non-synonymous polymorphism situated in the translation start site of VDR. The C variant results in a truncated protein, 3 amino acids shorter, with higher activity [11]. Studies have shown that carriers of the T variant, expressing a VDR-protein with lower activity, are more susceptible to different cancer forms, including
influence of abused substances, member of a Sports fed-
NSAID, positive for hepatitis or HIV, being under the
ongoing hormonal therapy treatment, treatment with
urine samples [18]. Exclusion criteria in the study were
different doses of testosterone and doping analysis in
was measured with AutoDELFIA using a AutoDELFIA
cal method on a Roche Cobas e602 after preparation with
the respective study was performed. In cohort 1 (ana-
at the division of clinical pharmacology, at the time when
were collected at the inclusion of the study.
were positive on AAS. The participants were clinically
Urine samples were collected and 84% of the participants
were asked to participate when they contacted the Anti-
formed at our unit between 1993 and 2000 where men
57 years old. They were recruited to a previous study per-
cenTRs given supra-physiological doses of testoster-
27–43 years [2]. The participants were given a single
intramuscular dose of 500 mg testosterone enanthate
(Testoviron® Depot) with the primary end-point to study
different doses of testosterone and doping analysis in
samples [18]. Exclusion criteria in the study were
ongoing hormonal therapy treatment, treatment with
NSAID, positive for hepatitis or HIV, being under the
fluence of abused substances, member of a Sports fed-
eration, malignancy within the last 5 years prior to study
entry or allergy towards the compounds given. Blood
samples were collected prior to (Day 0), and 4 and 14 days
after testosterone administration. Blood samples were
collected between 7.00 am and 9.00 am after an overnight
fast. Cohort 2 consisted of AAS abusers between 18 and
57 years old. They were recruited to a previous study per-
 that time is not available.
Genomic DNA was isolated from 200 µl peripheral
blood (Cohort 1) and from serum (Cohort 2) using the
DNA Blood Mini kit (Cat No. 51104; Qiagen, Hilden
Germany). Allelic discrimination reactions were per-
formed using TaqMan® genotyping assays (Cat No.
4351379; Applied Biosystems, Foster City CA USA): C__12060045_20 for VDR (rs2228570); C__2404008_10
for VDR (rs731236). The final volume of each reaction
was 10 µl consisting of 10–30 ng DNA and 2×Taqman
Universal PCR Master mix (LifeTechnology, Applied
Biosystems, Catalog no 4440047). The PCR profile con-
sisted of 95 °C for 10 min followed by 40 cycles of 92 °C
for 15 s and 60 °C for 1 min. The fluorescence signal was
measured with an ABI 7500 Sequence detector (Applied
Biosystems).
All statistical tests were performed using GraphPad
Prism (San Diego, California, USA) v. 6.00 and values of
p ≤ 0.05 were considered statistically significant. Since
the hormone levels of gonadotropins are not normally
distributed, non-parametric Mann–Whitney U test was
used.

Results
In Cohort 1 the genotype frequencies were Fok1
CC = 53%, TC = 26% and TT = 21% and for TaqI
TT = 37%, TC = 63% and CC = 0%, respectively. The
Fok1 polymorphism was associated with the LH con-
centration at baseline as well as after 4 and 14 days after
the testosterone dose. Individuals homozygous for CC
had 30% higher LH concentration at baseline compared
to T-carriers; mean 4.2 ± 0.9 compared to 3.2 ± 1.2
(p = 0.04). At 4 and 14 days, the LH concentrations were
approximately twice as high in the CC subjects com-
pared to the T-carriers; mean 1.5 ± 1.3 and 0.33 ± 0.29
compared to 0.73 ± 0.71 and 0.18 ± 0.10, (p = 0.04 and
p = 0.01) (Fig. 1). There was no association between the
Fok1 SNP and FSH concentration at any time (Fig. 1). The
TaqI VDR genotype (rs731236) was not associated with
LH and FSH concentrations at any of the time points
(Fig. 1). The genotype frequencies of both SNPs were in
Hardy–Weinberg (HW) equilibrium.
In order to confirm the findings in Cohort 1 we geno-
typed samples obtained from AAS users. When the sub-
jects showed up for the first visit, serum samples were
collected. The time span from their last intake of AAS
varied between a few days and some months. The geno-
type frequencies of TaqI were TT = 49%, TC = 42% and

Main text
Methods
Two cohorts of individuals were included; healthy vol-
teers given supra-physiological doses of testoster-
one (n = 25) and one group of self-reporting AAS users
(n = 45). The study population of cohort 1 has been
described earlier and included 25 male volunteers aged
TC = 42% and

ovarian cancer [12–15], and have an impaired immune
system [16, 17]. However, this SNP has never been stud-
ied in relation to LH and FSH concentrations.
The aim of this pilot-study was to investigate the asso-
ciation between VDR rs2228570 and rs731236 polymor-
phisms and the levels of LH and FSH in relation to AAS
use. To this end post hoc analysis of material from two
previous performed studies were used.
CC = 9% and for Fok1 see Table 1. In summary, the LH levels were significantly lower than the baseline levels observed in the healthy volunteers (p < 0.001) as a result of their AAS use. A significant association between the Fok1 VDR polymorphism and the LH concentration was found also in Cohort 2, whereas no association was found between this SNP and the FSH concentration (Table 1). Individuals homozygous for the C-allele had significantly higher LH levels than carriers of the T-allele (p < 0.05) and four times higher levels than TT-individuals (p < 0.05). The genotype frequency of rs2228570 was in HW equilibrium, whereas the genotype frequency of rs731236 was not (p = 0.04).

**Discussion**

The results from this study show that individuals homozygous for the T-allele of the VDR polymorphism Fok1 (rs2228570) have lower circulatory LH levels than carriers of the C-allele in two different populations. The difference in LH concentration between the genotype groups was larger after the administration of a supra-physiological dose of testosterone and in self-reporting AAS users as compared to baseline values. This is the
first time a VDR polymorphism is shown to be associated with serum levels of LH in relation to AAS use.

The Fok1 (rs558750) C-allele leads to a truncated protein, three amino acids shorter than the wildtype T-variant. The C-allele has been associated with higher activity in vitro [11]. Subjects with the T-allele, i.e. expressing the protein with lower activity, have been shown to have increased risk of hormonal dependent cancers, such as ovarian [14, 21] and prostate cancer [22]. The association with breast cancer seems to be weaker and different studies have shown divergent results [23–25].

It has previously been reported that serum LH concentrations in women with previously un-diagnosed PCOS are associated with the VDR TaqI (rs731236) polymorphism [9]. PCOS is a disorder where women have naturally higher concentrations of circulatory androgens as well as LH [26, 27]. We could not find any association between the rs731236 polymorphism and gonadotropin concentrations in the cohorts studied here. It is possible that the VDR genotypes exert different gender and/or disorder effects [28]. Based on these data it seems that androgens, whether endogenous or exogenous seem to amplify the genetic association with the circulatory LH concentrations. A recent GWAS study including 2913 individuals (294 males) identified that a genetic variant near the FSHB gene was associated with LH levels [29].

LH is produced exclusively in the gonadotropic cells of the anterior pituitary. VDR is abundant in the human pituitary [30] and it is plausible that VDR may be involved in the synthesis of gonadotropins and that the more efficient VDR C-allele is associated with an increased transcriptional activity of genes required for the synthesis of LH subunits. FSH levels were not affected by the VDR polymorphism. FSH is partly regulated by other mechanisms than LH. For example, inhibin and activin from the sertoli cells affects the FSH levels independently of androgens.

Several studies have shown that vitamin D deficiency is associated with low testosterone levels in men [5, 7], which may be accompanied by low levels of gonadotropins [8]. Wehr et al. hypothesized that vitamin D may have an impact directly on the gonadal function since testosterone and vitamin D displayed a concordant seasonal pattern [31]. Moreover supplementation with vitamin D increases the total testosterone levels in some studies [32]. Therefore, it is of clinical interest to further investigate how vitamin D and the VDR mediated effect is involved in the regulation of the HPG-axis.

Supra-physiological doses of androgens are known to suppress LH and FSH with a fast response that may persist for a long time [3]. The resulting hypogonadism has been associated with the more distressing AAS induced side effects, such as depression and sexual dysfunction [33, 34]. The degree of suppression and the ability to recover after an AAS cycle depends on the duration of AAS use and the cumulative dose [35].

However, these findings are not only of interest in relation to AAS abuse but also to men with iatrogenically suppressed LH-levels, as in prostate cancer patients on hormonal therapy. Indeed, the Fok1 VDR polymorphism has been associated with the prognosis in prostate cancer [36]. If the results presented here also apply to women it may indicate that subjects homozygous for the T-allele would have an even higher suppression of their LH-levels when taking contraceptives than in subjects with the C-allele. The results might also contribute to the understanding of the increased risk of ovarian cancers in women with the T-allele [14, 21].

In conclusion, we show an association between LH levels and the Fok1 VDR polymorphism and that this difference is even more pronounced in AAS users and subjects with suppressed LH levels. The role of VDR in the synthesis and secretion of LH warrants further studies.

Limitations
This study has some limitations that need to be considered. The population included male subjects who self-reported AAS use, different doses and administration routes have been used, and the time elapsed since their last AAS intake varied between some days to some months. However, it is not possible to conduct a controlled study using the high doses AAS users normally use. In human studies, lower doses and/or single doses are given. Another limitation is the small number of subjects included. Still, the same findings are present in both cohorts although they are collected with more than 10 years in between. The hormone analysis in Cohort 2 was analyzed in year 2000 and the method used at this time was not as sensitive as the methods used today. The lower detection limit for LH was then only 0.7 IU/L. It is possible that with a more sensitive method employed today an even larger association of the Fok1 genotype and LH secretion could have been discerned.

Abbreviations
AAS: anabolic androgenic steroids; ASIH: anabolic steroid induced hypogonadism; FSH: follicle stimulating hormone; LH: luteinizing hormone; SNP: single nucleotide polymorphism; VDR: vitamin D receptor.

Authors’ contributions
LB8 and LE designed the study, performed the analysis and wrote the first draft of the manuscript. ML and AR conducted the original studies (cohort 1 and 2), were involved in the interpretation of the data and contributed to the writing of the final version of the manuscript. All authors read and approved the final manuscript.

Author details
1 Division of Clinical Microbiology F68, Department of Laboratory Medicine, Karolinska University Hospital, Karolinska Institutet, Huddinge, 141
86 Stockholm, Sweden. ² Department of Medicine, Division of Endocrinology, Metabolism and Diabetesm Karolinska Institutet, Karolinska University Hospital, Huddinge, 141 86 Stockholm, Sweden. ³ Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital, Huddinge, 141 86 Stockholm, Sweden.

Acknowledgements
The authors are grateful to Dr. Nina Gårevik for excellent work with the clinical studies in this project.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
Raw data are available from the corresponding author upon request.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Both studies [2, 19] were approved by the Regional Ethical Committee at Karolinska Institutet and performed in accordance with Declaration of Helsinki, Dnr 186/98 and 2008/187-31. Study 1 were also approved by the Swedish Medical Product Agency. Written informed consent was obtained from all participants before inclusion in the studies.

Funding
Financial support was provided through the Regional agreement on training and clinical research (ALF) between Karolinska Institutet and Stockholm County Council, The Swedish Cancer Society and Karolinska Institutet.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 5 November 2017    Accepted: 12 January 2018

References
1. Garevik N, Borjeson A, Choong E, Ekstrom L, Lehtihet M. Impact of single-dose nandrolone decanoate on gonadotropins, blood lipids and HMG-CoA reductase in healthy men. Andrologia. 2016;48(5):595–600.
2. Garevik N, Rane A, Björkhem-Bergman L, Ekstrom L. Effects of different doses of testosterone on gonadotropins, 25-hydroxyvitamin D3, and blood lipids in healthy men. Subst Abuse Rehabil. 2014;5:121–7.
3. Jarow JP, Lipshultz LI. Anabolic steroid-induced hypogonadotropic hypogonadism. Am J Sports Med. 1990;18(4):429–31.
4. Flanagan JN, Lehtihet M. The response to gonadotropin-releasing hormone and HCG in men with prior chronic androgen steroid abuse and clinical hypogonadism. Horm Metab Res. 2015;47(9):668–73.
5. Lee DM, Tajar A, Pye SR, Boonen S, Vanderschueren D, Bouillon R, O'Neill MW, et al. Association between vitamin D concentration and levels of sex biochemical parameters of women with polycystic ovary syndrome. J Assist Reprod Genet. 2011;28(3):225–32.
6. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eiseman JA. Prediction of bone density from vitamin D receptor alleles. Nature. 1994;367(6460):284–7.
7. Ara H, Miyamoto K, Taketani Y, Yamamoto H, Iemon Y, Morita K, Tonai T, Nishishito T, Mori S, Takeda E. A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J Bone Miner Res. 1997;12(6):915–21.
8. Kaabachi W, Kaabachi S, Rafrafi A, Amor AB, Tizaoui K, Haj Sassi F, Hamzaoui K. Association of vitamin D receptor FokI and Apal polymorphisms with lung cancer risk in Tunisian population. Mol Biol Rep. 2014;41(10):6545–53.
9. Li L, Shang F, Zhang W, Zhang C, Li J, Wang C, Wei L. Role of vitamin D receptor gene polymorphisms in pancreatic cancer: a case-control study in China. Tumour Biol. 2015;36(6):4707–14.
10. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eiseman JA. Prediction of bone density from vitamin D receptor alleles. Nature. 1994;367(6460):284–7.
11. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eiseman JA. Prediction of bone density from vitamin D receptor alleles. Nature. 1994;367(6460):284–7.
12. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eiseman JA. Prediction of bone density from vitamin D receptor alleles. Nature. 1994;367(6460):284–7.
13. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eiseman JA. Prediction of bone density from vitamin D receptor alleles. Nature. 1994;367(6460):284–7.
14. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eiseman JA. Prediction of bone density from vitamin D receptor alleles. Nature. 1994;367(6460):284–7.
15. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eiseman JA. Prediction of bone density from vitamin D receptor alleles. Nature. 1994;367(6460):284–7.
16. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eiseman JA. Prediction of bone density from vitamin D receptor alleles. Nature. 1994;367(6460):284–7.
17. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eiseman JA. Prediction of bone density from vitamin D receptor alleles. Nature. 1994;367(6460):284–7.
18. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eiseman JA. Prediction of bone density from vitamin D receptor alleles. Nature. 1994;367(6460):284–7.
19. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eiseman JA. Prediction of bone density from vitamin D receptor alleles. Nature. 1994;367(6460):284–7.
20. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eiseman JA. Prediction of bone density from vitamin D receptor alleles. Nature. 1994;367(6460):284–7.
hormones in an elderly Polish population with different genotypes of VDR polymorphisms (rs10735810, rs1544410, rs7975232, rs731236). Gene. 2015;559(1):73–6.

29. Ruth KS, Campbell PJ, Chew S, Lim EM, Hadlow N, Stuckey BG, Brown SJ, Feenstra B, Joseph J, Surdulescu GL, et al. Genome-wide association study with 1000 genomes imputation identifies signals for nine sex hormone-related phenotypes. Eur J Hum Genet. 2016;24(2):284–90.

30. Perez-Fernandez R, Alonso M, Segura C, Munoz J, Garcia-Caballero T, Diguez C. Vitamin D receptor gene expression in human pituitary gland. Life Sci. 1997;60(1):35–42.

31. Wehr E, Pilz S, Boehm BO, Marz W, Obermayer-Pietsch B. Association of vitamin D status with serum androgen levels in men. Clin Endocrinol. 2010;73(2):243–8.

32. Pilz S, Frisch S, Koertke H, Kuhn J, Dreier J, Obermayer-Pietsch B, Wehr E, Zittermann A. Effect of vitamin D supplementation on testosterone levels in men. Horm Metab Res. 2011;43(3):223–5.

33. Coward RM, Rajanahally S, Kovac JR, Smith RP, Pastuszak AW, Lipshultz LI. Anabolic steroid induced hypogonadism in young men. J Urol. 2013;190(6):2200–5.

34. Parkinson AB, Evans NA. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc. 2006;38(4):644–51.

35. Tan RS, Scally VC. Anabolic steroid-induced hypogonadism—towards a unified hypothesis of anabolic steroid action. Med Hypotheses. 2009;72(6):723–8.

36. Pao JB, Yang YP, Huang CN, Huang SP, Hour TC, Chang TY, Lan YH, Lu TL, Lee HZ, Juang SH, et al. Vitamin D receptor gene variants and clinical outcomes after androgen-deprivation therapy for prostate cancer. World J Urol. 2013;31(2):281–7.